MA28747B1 - Dérivés de pyridine - Google Patents

Dérivés de pyridine

Info

Publication number
MA28747B1
MA28747B1 MA29626A MA29626A MA28747B1 MA 28747 B1 MA28747 B1 MA 28747B1 MA 29626 A MA29626 A MA 29626A MA 29626 A MA29626 A MA 29626A MA 28747 B1 MA28747 B1 MA 28747B1
Authority
MA
Morocco
Prior art keywords
pyridine derivatives
compounds
preparation
solvates
pain
Prior art date
Application number
MA29626A
Other languages
English (en)
Inventor
Charlotte Alice Louise Lane
Graham Nigel Maw
David James Rawson
Lisa Rosemary Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0416524A external-priority patent/GB0416524D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA28747B1 publication Critical patent/MA28747B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"Dérivés de pyridine" La présente invention concerne des composés de formule (I) et leurs sels et produits de solvatation pharmaceutiquement acceptables, des procédés pour la préparation de, les intermédiaires utilisés dans la préparation de, et des compositions contenant ces composés et les utilisations de ces composés pour le traitement de la douleur.
MA29626A 2004-07-23 2007-01-23 Dérivés de pyridine MA28747B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0416524A GB0416524D0 (en) 2004-07-23 2004-07-23 Pyridine derivatives
US64607705P 2005-01-21 2005-01-21

Publications (1)

Publication Number Publication Date
MA28747B1 true MA28747B1 (fr) 2007-07-02

Family

ID=35786566

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29626A MA28747B1 (fr) 2004-07-23 2007-01-23 Dérivés de pyridine

Country Status (17)

Country Link
US (1) US7649004B2 (fr)
EP (1) EP1802580A2 (fr)
JP (1) JP4056081B1 (fr)
KR (1) KR20070026845A (fr)
AP (1) AP2007003887A0 (fr)
AU (1) AU2005266090A1 (fr)
BR (1) BRPI0513717A (fr)
CA (1) CA2574600C (fr)
CR (1) CR8859A (fr)
EA (1) EA200700099A1 (fr)
EC (1) ECSP077185A (fr)
IL (1) IL180430A0 (fr)
MA (1) MA28747B1 (fr)
MX (1) MX2007000885A (fr)
NO (1) NO20066055L (fr)
TN (1) TNSN07022A1 (fr)
WO (1) WO2006011050A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
WO2007083239A1 (fr) * 2006-01-23 2007-07-26 Pfizer Limited Dérivés de pyridine en tant que modulateurs du canal sodium
GEP20125379B (en) * 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
WO2008135830A1 (fr) * 2007-05-03 2008-11-13 Pfizer Limited Dérivés de pyrazine
WO2011016234A1 (fr) 2009-08-04 2011-02-10 Raqualia Pharma Inc. Dérivés de picolinamide bloqueurs de ttx-s
US9394293B2 (en) 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
KR102295748B1 (ko) 2013-01-31 2021-09-01 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 피리돈 아미드
CN105073738B (zh) 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
CA2900604A1 (fr) * 2013-03-15 2014-09-25 Chromocell Corporation Modulateurs du canal sodique pour le traitement de la douleur
ES2654393T3 (es) 2013-07-19 2018-02-13 Vertex Pharmaceuticals Incorporated Sulfonamidas como moduladores de los canales de sodio
UA120353C2 (uk) * 2013-09-10 2019-11-25 Хромоселл Корпорейшн Модулятори натрієвого каналу для лікування болю і діабету
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
MA41938A (fr) * 2015-04-21 2018-02-28 Almirall Sa Dérivés hétérocycliques amino-substitués utilisés comme inhibiteurs des canaux sodiques
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
WO2019157505A1 (fr) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated Méthode de traitement de la douleur
WO2020146612A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters et carbamates utilisés en tant que modulateurs de canaux sodiques
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (fr) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8
WO2020219867A1 (fr) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur
CA3164134A1 (fr) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Tetrahydrofuranes substitues en tant que modulateurs de canaux sodiques
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
MA64856B1 (fr) 2021-06-04 2026-02-27 Vertex Pharmaceuticals Incorporated Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide
CA3221788A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Tetrahydrofuran-2-carboxamides substitues utiles en tant que modulateurs de canaux sodiques
WO2022256676A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Analogues de tétrahydrofurane substitués utiles en tant que modulateurs de canaux sodiques
JP2024520643A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン
JP2024520646A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
GEAP202516634A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor
AU2023391870A1 (en) 2022-12-06 2025-06-05 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2025090465A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Composés hétéroaryle pour le traitement de la douleur
WO2025090480A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Composés hétéroaryles pour le traitement de la douleur
WO2025090516A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Procédés de préparation de composés pour le traitement de la douleur et de formes solides de ceux-ci
WO2025090511A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Procédés de préparation de modulateurs de canaux sodiques et formes solides de ceux-ci pour le traitement de la douleur
WO2025122953A1 (fr) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Schémas posologiques et formulations de suzétrigine pour le traitement des douleurs sévères et chroniques
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (fr) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Composés dérivés d'oxazolidone et leur utilisation dans le traitement de la douleur chronique et aiguë
WO2026030525A1 (fr) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Formes galéniques et schémas posologiques de zilvétrigine pour le traitement de la douleur

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3332687A1 (de) 1983-09-10 1985-03-28 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2-amino-alkylpyridinen
JPS63179869A (ja) 1987-01-20 1988-07-23 Dainippon Pharmaceut Co Ltd ピペリジン誘導体
DE3933802A1 (de) 1989-10-10 1991-04-18 Basf Ag Pyridinderivate und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
CN1034934C (zh) 1990-06-19 1997-05-21 明治制果株式会社 血管紧张素ii拮抗性吡啶衍生物的制备方法
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
WO1996018617A1 (fr) 1994-12-12 1996-06-20 Merck & Co., Inc. Pyridines 2-acylaminees substitutees utilisees comme inhibiteurs de synthase d'oxyde d'azote
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
JPH09132529A (ja) 1995-11-09 1997-05-20 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
AU706150B2 (en) 1996-04-03 1999-06-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249650A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
DE19831246A1 (de) 1998-07-11 2000-01-13 Clariant Gmbh Verfahren zur Herstellung von Arylpyridinen
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
EA200700099A1 (ru) 2007-08-31
JP2008507503A (ja) 2008-03-13
BRPI0513717A (pt) 2008-05-13
KR20070026845A (ko) 2007-03-08
CR8859A (es) 2007-03-02
ECSP077185A (es) 2007-02-28
AU2005266090A1 (en) 2006-02-02
CA2574600C (fr) 2010-08-31
NO20066055L (no) 2007-01-24
CA2574600A1 (fr) 2006-02-02
US20080312235A1 (en) 2008-12-18
TNSN07022A1 (fr) 2008-06-02
JP4056081B1 (ja) 2008-03-05
MX2007000885A (es) 2007-03-12
WO2006011050A2 (fr) 2006-02-02
EP1802580A2 (fr) 2007-07-04
US7649004B2 (en) 2010-01-19
WO2006011050A3 (fr) 2006-10-05
IL180430A0 (en) 2007-06-03
AP2007003887A0 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
MA28747B1 (fr) Dérivés de pyridine
MA29926B1 (fr) Derives de pyrazine
TN2009000450A1 (fr) Derives de pyridine
MA31894B1 (fr) Composes organiques
TN2011000316A1 (fr) Derives de sulfonamides
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA29791B1 (fr) Composes therapeutiques.
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA31754B1 (fr) Cis-imidazolines chirales
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
TN2009000138A1 (fr) Biaryl-ether-urees
MA31766B1 (fr) Composés organiques
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA27801A1 (fr) Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant
MA27775A1 (fr) Composes organiques
MA24729A1 (fr) Macrolides nouveaux.